Recently, several blockbuster clinical studies have been released. As an SGLT2 inhibitor, canagliflozin API powder has demonstrated unprecedented cardiorenal protection value in the field of diabetes treatment, bringing new treatment hope to hundreds of millions of diabetes patients worldwide.
Dose dependent cardiovascular benefits confirmed for the first time
At the 62nd Annual Meeting of the European Society of Nephrology (ERA2025), the China Medical Forum invited a team of Academician Liu Zhihong from the National Clinical Research Center for Kidney Disease at the Eastern Theater Command General Hospital to provide an in-depth interpretation of the post hoc analysis results of CANVAS research. This study, which included 4330 patients with type 2 diabetes mellitus and high cardiovascular risk, showed that there was a dose-dependent effect of TA 7284 powder on cardiovascular endpoints.
The research results showed that compared with placebo, 300mg canagliflozin significantly reduced the incidence of composite cardiovascular endpoints (non fatal myocardial infarction, stroke, or cardiovascular death) by 17% (HR 0.83, 95% CI 0.68-1.00; p=0.049), while the 100mg dose group did not show statistical differences. Even more excitingly, the 300mg group of significantly reduced all-cause mortality by 22% (HR 0.78, 95% CI 0.63-0.97; p=0.027).
Significant breakthrough in renal protection
In terms of kidney protection, it also performs well. Research has shown that compared to placebo, 100mg and 300mg of Canagliflozin raw materials significantly reduce the risk of composite renal endpoints by 50% and 58%, respectively. It is worth noting that the 300mg group reduced the risk of progression of albuminuria by 17%, while the 100mg group did not show this result, once again confirming its dose-dependent effect.
CREDENCE study, as the first study on the renal protection function of hypoglycemic drugs, confirmed that the rational use of CS-183 can reduce the risk of renal function deterioration, renal dialysis/transplantation and renal or cardiovascular death in patients with diabetes nephropathy by at least 30%. This breakthrough research progress led the American diabetes Association (ADA) to urgently revise the guidelines after they were released, raising the evidence level of SGLT2 inhibitors from C to A.
New treatment options for children and adolescents
In August 2025, the results of an international phase III randomized clinical trial for type 2 diabetes patients aged 10-18 years will be published in the Annals of Internal Medicine. This study involving 104 centers in 10 countries showed that it significantly reduced glycated hemoglobin levels by 1.13% at 26 weeks, with better efficacy than placebo and safety consistent with adults. At 52 weeks, 30.9% of patients had HbA1c controlled below 6.5% and no severe hypoglycemic events occurred.
Unique mechanism of heart kidney benefits
The uniqueness of Invokana lies in its dual mechanism of action. As an SGLT2 inhibitor, it reduces blood glucose levels by inhibiting the reabsorption of glucose by the proximal tubules of the kidney, increasing urinary glucose excretion. More importantly, it achieves renal protection from a mechanistic perspective by improving glomerular hemodynamics and reducing glomerular pressure.
In terms of cardiovascular protection, it works through multiple pathways: lowering blood pressure, reducing weight, improving myocardial energy metabolism, and lowering cardiac load. According to research data from the World Health Organization, SGLT2 inhibitors can reduce the risk of all-cause mortality by 51% and heart failure by 39% in patients, with a high usage rate of 53% for JNJ 28431754 (canagliflozin).
Wide market prospects
With the continuous accumulation of clinical evidence, the Canaglifozion API powder market has broad prospects. Domestic companies such as Jiangsu Hengrui Pharmaceutical, Zhejiang Huahai Pharmaceutical, and Shanghai Fosun Pharmaceutical have already established their presence in the Cagliflozin market, with Jiangsu Hengrui Pharmaceutical holding a market share of 35%. In October 2025, Xi'an Faithful BioTech Co., Ltd obtained the "Drug Registration Certificate" approved and issued by the National Medical Products Administration, injecting new vitality into the market.
Expert opinion
Academician Liu Zhihong, National Center for Clinical Medicine of Kidney Diseases, Eastern Theater General Hospital, said: "After-the-fact analysis of the CANVAS study showed that its influence on cardiovascular endpoint was dose-dependent, which provided important guidance for clinical practice. In patients with type 2 diabetes with high cardiovascular risk, we can consider using a higher dose of raw powder Cagliflozin . "
Professor Xiao Xinhua, chief physician of Endocrinology Department of Peking Union Medical College Hospital, stressed: "CREDENCE research is a major breakthrough in the treatment of diabetic nephropathy in recent 20 years. To control diabetic nephropathy, timely screening, timely diagnosis and effective drug treatment are needed. Its renal protection provides new treatment options for patients. "
Future prospects
With the accumulation of more clinical data and the update of guidelines, its position in the treatment of diabetes will be further enhanced. In the future, Canagliflozin api is expected to be used in a wider range of people, including patients with non-diabetic nephropathy and patients of different ages.
The research and application of Canaglifozion marks a new era of diabetes treatment-from simple hypoglycemic to comprehensive protection of heart and kidney, which brings new hope to hundreds of millions of diabetic patients around the world.
What are the advantages of the Canagliflozin API powder we provide?
Having the following core advantages is the solid foundation for us to become your ideal partner:
1, Core advantages: Excellent quality and compliance assurance
Our Canagliflozin API powder adopts a strictly controlled synthesis and purification process to ensure a stable purity of over 99.5% for the main components, with extremely low content of relevant substances, in line with the latest standards of pharmacopoeias in various countries. The production process is completed in modern workshops that have obtained China NMPA certification and comply with international cGMP standards, with a complete traceability system to provide you with reliable quality assurance.
2, Key Differentiation: Professional Services and Stable Supply
We understand that your needs are not limited to just products. As a supplier specializing in active pharmaceutical ingredients, we can provide customized solutions in specific crystal forms, particle size distributions, and other aspects based on your formulation research and development needs. Relying on a stable supply chain system, we can achieve stable large-scale production and on-time delivery, fully supporting your project schedule and market plan.
Choosing us means that you not only receive high-quality raw materials, but also a reliable partner dedicated to providing solutions. If you need to learn more about product specifications, technical information, or conduct business negotiations, please feel free to contact us through the following email: 📧 sales6@faithfulbio.com
Our professional team will provide you with detailed and timely response and service.
Disclaimer: The information published on this website comes from the internet, which does not mean that this website agrees with its views or confirms the authenticity of the content. Please pay attention to distinguish it. In addition, the products provided by our company are only used for scientific research. We are not responsible for the consequences of any improper use. If you are interested in our products, or have critical suggestions on our articles or are not completely satisfied with the products received, Please also contact us via Email ：sales6@faithfulbio.com ; Our team is committed to ensuring the complete satisfaction of customers.